West Orange, NJ, United States
West Orange, NJ, United States

Time filter

Source Type

An ASCO-CAP expert panel is developing this focused update to address new information made available since the guideline's previous update in 2013. Notably, this 2017 Focused Update will address uncommon clinical scenarios to improve clarity, particularly for infrequent HER2 test results that are of uncertain biologic or clinical significance. All stakeholders—oncologists, pathologists, nurses, allied health professionals, patients, and patient advocates—can weigh-in on the online at cap.org. All health systems with all levels of immunohistochemistry (IHC) experience, including U.S. and international-based laboratories, are encouraged to submit comments. Input regarding clinical concerns, proposed testing algorithm and any published or unpublished data is welcomed. The expert panel of pathologists and oncologists convened by ASCO and CAP will assess feedback submitted, and revise the draft recommendations as necessary. The panel targets publication later this year. Until the official release and publication of the 2017 Focused Update, ASCO and CAP recommend that oncologists and pathologists continue to . "The 2017 HER2 Testing Focused Update addresses studies published since 2013, when we last updated the HER2 testing guideline for breast cancer. Notably, these studies help us better evaluate less common patterns of HER2 tests results by in-situ hybridization (ISH) that have limited clinical outcome data," panel co-chair for CAP, Elizabeth Hammond, MD, FCAP, said. "Ultimately, this update should help pathologists and oncologists integrate the information offered by high-quality HER2 IHC and ISH testing to provide the most accurate diagnosis." Dr. Hammond is professor of pathology at the University of Utah School of Medicine. According to ASCO co-chair Antonio Wolff, MD, FACP, FASCO, professor of oncology at Johns Hopkins, "Guidelines are living documents that must evolve based on high-level clinical and laboratory evidence, along with, in this case, feedback from experienced pathology laboratories. In this focused update, we are combining all these elements and the experience of an expert guideline panel to draft a set of recommendations that we hope will help health systems and pathologists offer oncologists the most accurate information on test results to inform clinical decisions and favorably impact patient care." The ASCO/CAP HER2 testing guideline focused update addresses five clinical questions raised following the publication of the 2013 guideline update. The panel addressed specific testing strategies to better define and distinguish HER2 status of tumors. Specifically, the draft update recommends: The information, data, and draft recommendations provided by ASCO and the CAP during open comment period are presented for informational and public feedback purposes only. Draft materials are not to be stored, adapted, or redistributed in any manner. ASCO and CAP also invite feedback from oncologists, pathologists, and all stakeholders on the "2010 ASCO/CAP Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer." The ASCO-CAP panel will assess feedback to evaluate any possible revisions to the 2010 guideline. No official date for release of a guideline update has been set. About ASCO Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at ASCO.ORG, explore patient education resources at Cancer.NET, and follow us on Facebook, Twitter, LinkedIn, and YouTube. About CAP As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, READ THE CAP ANNUAL REPORT at CAP.ORG To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asco-and-the-cap-invite-comment-on-focused-update-to-her2-testing-guideline-in-breast-cancer-300461491.html


Visiongain's new report Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques indicates that the...


WASHINGTON, May 22, 2017 /PRNewswire/ -- Oscar nominee and Emmy and Tony-Award winner Laurence Fishburne (BLACK-ISH) will join Tony Award-winner Joe Mantegna (CRIMINAL MINDS) to host the 28th annual edition of PBS' NATIONAL MEMORIAL DAY CONCERT.  For almost three decades, PBS has inspired...


Oscar nominee and Emmy and Tony-Award winner Laurence Fishburne (BLACK-ISH) and Tony Award-winner Joe Mantegna (CRIMINAL MINDS) co-host the NATIONAL MEMORIAL DAY CONCERT.  The all-star line-up also includes: distinguished American leader General Colin L. Powell USA (Ret.); Emmy Award-winner Gary Sinise (CRIMINAL MINDS: WITHOUT BORDERS); world-renowned four-time Grammy Award-winning classical superstar Renée Fleming; multi-platinum recording artist and star of television, film and the Broadway stage Vanessa Williams; country music superstar Scotty McCreery; Grammy nominated, multi-platinum selling artist John Ondrasik of Five for Fighting; acclaimed actor John Ortiz (A DOG'S PURPOSE; KONG: SKULL ISLAND); Broadway and television star Christopher Jackson (HAMILTON, BULL); distinguished actress Ana Ortiz (UGLY BETTY, DEVIOUS MAIDS); legendary Irish Tenor Ronan Tynan; and the UK's best-selling cross-over artist Russell Watson; in performance with the National Symphony Orchestra under the direction of top pops conductor Jack Everly.  The gifted actress and singer Auli'i Cravalho (MOANA) will open the show with a special performance of the "National Anthem." The program is a co-production of Michael Colbert of Capital Concerts and WETA, Washington, D.C.  Executive producer Michael Colbert has assembled an award-winning production team that features the top Hollywood talent behind some of television's most prestigious entertainment awards shows including the GRAMMY AWARDS, COUNTRY MUSIC AWARDS, TONY AWARDS, SATURDAY NIGHT LIVE, and more. Capital Concerts is the production force behind two of television's longest-running and highest-rated live programs commemorating America's most important holidays.  THE NATIONAL MEMORIAL DAY CONCERT, the nation's tribute to our men and women in uniform, and A CAPITOL FOURTH, our country's biggest birthday party, have become American traditions that have consistently ranked among the highest rated programs on PBS over the past decade.  The holiday specials have been honored with over 80 awards including the New York Film Festival Award, the Telly Award, the Golden Cine Award, the National Education Association Award, the Christopher Award and the Writer's Guild of America Award. The NATIONAL MEMORIAL DAY CONCERT is made possible by grants from the Lockheed Martin Corporation, the National Park Service, the Corporation for Public Broadcasting, the Department of the Army, General Dynamics, PBS and public television stations nationwide.  Air travel is provided by American Airlines. For images and additional information, visit PBS Pressroom at www.pbs.org/pressroom To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/robert-patrick-and-mary-mccormack-join-the-cast-of-pbs-national-memorial-day-concert-an-american-tradition-honoring-our-heroes-past-and-present-300458853.html


News Article | May 4, 2017
Site: www.kandbnews.co.uk

Editor Philippa Turrell looks at the show barometer ISH to gauge how bathroom industry is performing


News Article | April 17, 2017
Site: www.prweb.com

SMIXIN AG, a leading Swiss clean-tech company, was recently presented with a special award – the prestigious "AIT: Innovation for Architecture and Technology" award, for its highly innovative hand washing station, COMBI. SMIXIN received this award at ISH 2017 – the world’s largest fair for sanitary equipment - on 14.03.2017. The COMBI water-saving hand washing station brings together the functions of water, soap & paper dispenser, sink and bin in a confined and controlled space. Further, the COMBI saves approximately 90% of water and 60% of soap versus a conventional hand washing device. SMIXIN's technology relies on the uniquely patented "Smart Mixing Unit", which allows for an optimal mix of water, air, and soap. The SMIXIN hand washing systems are driven by complex electronics and touch-free technology to eliminate the risk of germ propagation. They can be linked to a cloud server with a WLAN transmitter, for a fully remote management of multiple COMBIs installed in various locations of a building. These hygiene aspects, the resource-saving advantages and the features of the COMBI were highlighted by the jury while giving away the award. The COMBI is meant for use inside and/or outside the washing rooms in offices, buildings, large public spaces and quick serving restaurants. SMIXIN AG is a limited company by shares and is registered in the canton of Berne, Switzerland. It was established in December 2009 as a spin-off of Creaholic, a Swiss innovation factory founded by Elmar Mock, co-inventor of the Swatch. The SMIXIN technology was originally developed within Creaholic and is covered by three international patent families, all of which have been granted. The SMIXIN technology enables the optimal dosing, metering and mixing of soap, water, and air. As a part of our expansion, we are leveraging the embedded electronics to connect the devices to a network and promote our connectivity modules. For additional information, contact Eric Ballestraz at eric.ballestraz@smixin.com, or call on +41 32 366 64 00. The PDF File is also available here: http://www.smixin.com/news/


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "miRNA Tools and Services Market by Product and Services, Technology and End User - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. The global miRNA tools and services market was valued at $146 million in 2015 and is expected to reach $620 million by 2022, growing at a CAGR of 23.4% during the forecast period. It is expected to witness significant growth owing to the rise in incidence of cancer, auto-immune, and cardiovascular diseases. In addition, miRNA molecules possess specific properties, such as higher tissue and organ specificity; and ability to cross the blood-brain barrier easily, that make them a favorable option to be used as biomarkers for a variety of neurological diseases, thereby driving the market growth. However, quantification challenges and development of in-use techniques, such as microarray, hamper the market growth. The global miRNA tools and services market is segmented on the basis of product, technique, end user, and geography. The miRNA tools and services market is bifurcated into research tools and services. Research tools market is further divided into reagents, kits, and consumables. On the other hand, the services market is classified into miRNA extraction services, quantification services, microarray services, sequencing services, functional studies services, and others. Based on techniques, the market is segmented into extraction tools, qRT-PCR, NGS, microarray, functional analysis tools (such as miRNA mimetics, inhibitors, and target site blockers), and others (such as labeling, ISH, and northern blotting tools). CHAPTER 4. GLOBAL miRNA TOOLS AND SERVICES MARKET, BY PRODUCTS AND SERVICES For more information about this report visit http://www.researchandmarkets.com/research/w66sqc/mirna_tools_and


Global Molecular Diagnostics Market by Technologies, Applications, Growth Trends and Forecast to 2021, New Findings by iHealthcareAnalyst, Inc. Molecular Diagnostics Market by Technologies (PCR, FISH, NGS, and Biochips) and Applications (Genomics, Proteomics, Oncology, Microbiology, Blood Screening, Prenatal and Newborn Screening and Women’s Health) and Forecast 2017-2021 Maryland Heights, MO, April 21, 2017 --( Browse Molecular Diagnostics Market by Technologies (PCR, FISH, NGS, and Biochips) and Applications (Genomics, Proteomics, Oncology, Microbiology, Blood Screening, Prenatal and Newborn Screening and Women’s Health) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/molecular-diagnostics-market/ The global molecular diagnostics market report estimates the market size (Revenue USD million - 2014 to 2021) and composition of this market based on underlying technologies and its applications, and also forecasts growth trends (CAGR% - 2017 to 2021). The technology market segment is divided by polymerase chain reaction (PCR), transcription mediated amplification (TMA), hybridization technique, microarray, sequencing and others, while the application market segment is classified into infectious diseases, blood donor screening and genomics. The global molecular diagnostics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global molecular diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global molecular diagnostics market and included in this report are Abbott Laboratories, Becton Dickinson & Company, Cepheid, Roche Diagnostics and others. 1. Technology 1.1. Biochips and Microfluidics 1.2. Hybridization (ISH and FISH) 1.3. Mass Spectrometry 1.4. Next Generation Sequencing 1.5. Polymerase Chain Reaction 1.6. Transcription Mediated Amplification (TMA) 1.7. Others 2. Application 2.1. Blood Screening 2.2. Genomics 2.3. Infectious Disease Testing 2.4. Microbiology 2.5. Oncology 2.6. Prenatal and Newborn Screening 2.7. Women’s Health 3. Geography (Region, Country) 3.1 North America (U.S., Canada) 3.2 Latin America (Brazil, Mexico, Rest of LA) 3.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4 Asia Pacific (Japan, China, India, Rest of APAC) 3.5 Rest of the World 4. Company Profiles 4.1. Abbott Laboratories 4.2. Affymetrix, Inc. 4.3. Agilent Technologies, Inc. 4.4. Alere, Inc. 4.5. bioMérieux SA 4.6. Bio-Rad Laboratories, Inc. 4.7. Cepheid, Inc. 4.8. Danaher Corporation 4.9. F. Hoffmann-La Roche Ltd. 4.10. Hologic, Inc. 4.11. Meridian Bioscience, Inc. 4.12. PerkinElmer, Inc. 4.13. Qiagen N.V. 4.14. Randox Laboratories, Ltd. 4.15. Siemens AG 4.16. Thermo Fisher Scientific, Inc. To request the Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/molecular-diagnostics-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 21, 2017 --( PR.com )-- As many molecular techniques and technologies such as polymerase chain reaction (PCR), transcription mediated amplification (TMA), hybridization technique, microarray, sequencing, etc. have made their expected transitions into the clinical arena, molecular diagnostics has become an integral part of clinical applications such as genomics, proteomics, oncology, microbiology, blood screening, prenatal and newborn screening and women’s health. Molecular diagnostics is defined as a class of diagnostic tests which identifies genetic and molecular biomarkers of an individual patient. These days, molecular diagnostics kits are being widely adopted for testing genetic diseases, cancer, hepatitis virus and hospital acquired infections, as well as for blood donor screening test for hepatitis and HIV.Browse Molecular Diagnostics Market by Technologies (PCR, FISH, NGS, and Biochips) and Applications (Genomics, Proteomics, Oncology, Microbiology, Blood Screening, Prenatal and Newborn Screening and Women’s Health) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/molecular-diagnostics-market/The global molecular diagnostics market report estimates the market size (Revenue USD million - 2014 to 2021) and composition of this market based on underlying technologies and its applications, and also forecasts growth trends (CAGR% - 2017 to 2021). The technology market segment is divided by polymerase chain reaction (PCR), transcription mediated amplification (TMA), hybridization technique, microarray, sequencing and others, while the application market segment is classified into infectious diseases, blood donor screening and genomics.The global molecular diagnostics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global molecular diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.Major players operating in the global molecular diagnostics market and included in this report are Abbott Laboratories, Becton Dickinson & Company, Cepheid, Roche Diagnostics and others.1. Technology1.1. Biochips and Microfluidics1.2. Hybridization (ISH and FISH)1.3. Mass Spectrometry1.4. Next Generation Sequencing1.5. Polymerase Chain Reaction1.6. Transcription Mediated Amplification (TMA)1.7. Others2. Application2.1. Blood Screening2.2. Genomics2.3. Infectious Disease Testing2.4. Microbiology2.5. Oncology2.6. Prenatal and Newborn Screening2.7. Women’s Health3. Geography (Region, Country)3.1 North America (U.S., Canada)3.2 Latin America (Brazil, Mexico, Rest of LA)3.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4 Asia Pacific (Japan, China, India, Rest of APAC)3.5 Rest of the World4. Company Profiles4.1. Abbott Laboratories4.2. Affymetrix, Inc.4.3. Agilent Technologies, Inc.4.4. Alere, Inc.4.5. bioMérieux SA4.6. Bio-Rad Laboratories, Inc.4.7. Cepheid, Inc.4.8. Danaher Corporation4.9. F. Hoffmann-La Roche Ltd.4.10. Hologic, Inc.4.11. Meridian Bioscience, Inc.4.12. PerkinElmer, Inc.4.13. Qiagen N.V.4.14. Randox Laboratories, Ltd.4.15. Siemens AG4.16. Thermo Fisher Scientific, Inc.To request the Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/molecular-diagnostics-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


News Article | May 3, 2017
Site: globenewswire.com

President and CEO Jyri Luomakoski comments on developments during the reporting period: This document is a condensed version of Uponor’s January – March 2017 interim report bulletin, which is attached to this release. It is also available on the company website. This interim report has been compiled in accordance with the IAS 34 reporting standards and is unaudited. The figures in brackets are the reference figures for the equivalent period in the previous year. Any change percentages are calculated from the exact figures and not the rounded figures published here. Webcast of the results briefing and the presentation A webcast in English will be broadcast on 3 May at 15.00 EET. Connection details are available at http://investors.uponor.com. The recorded webcast can be viewed at http://investors.uponor.com shortly after publication. The presentation document will be available at http://investors.uponor.com > News & downloads. Uponor Corporation will publish its half year financial report on 25 July 2017. During the silent period from 1 to 25 July, Uponor will not comment on market prospects or factors affecting business and performance. With confidence among builders at levels not seen since before the financial crisis, European construction markets entered the year with continued, positive momentum. In North America, broad-based growth continued in Uponor’s key building segments, but at a reduced rate. In Uponor’s largest Central European market, Germany, private consumption and public expenditure, combined with buoyant business confidence, have continued to boost the economy. Within the construction industry, the commercial construction market has been particularly strong, while other building segments have experienced lower growth. Some of the growth has been in the prefabricated house market, which has not been a core market for Uponor. The construction sentiment in Germany stumbled in the last months of 2016, but rebounded somewhat during the first months of 2017 and remains favourable compared to previous years. In the Netherlands, growth has moderated, but builders report significant improvements in their order books. In several European markets, the HVAC industry continues to be hampered by bottlenecks in planning and in professional installation services, which is slowing business. In Southern Europe, construction activity is primarily trending upward, with considerable improvements in the Spanish and French markets. Despite political uncertainties, no significant headwinds have been prevalent in UK demand. Supported by improving macroeconomic fundamentals, construction activity has grown across the Nordic countries. In Finland, non-residential projects have slowly begun to contribute to the recovery, which has thus far been driven by residential construction in growth centres. The Swedish market continues to outperform its neighbours, with housing starts growing significantly. The construction markets in Norway and Denmark are also both benefiting from strengthening economies. In North America, residential and non-residential construction remain largely healthy in the face of labour shortages in some industries and rising interest rates. In the USA, lacklustre business investments have slowed the pace of growth in non-residential construction projects, but construction spending has nevertheless grown from the same period last year. On the residential side, housing starts have sustained their steady, upward trend. In Canada, a recent - and probably temporary - surge in multi-family starts in urban areas has lent support to the residential market. With regard to Uponor’s infrastructure solutions, civil engineering expenditures in the Nordic countries remain modest, but steady, while an increase in non-residential building construction projects has improved demand. In Canada, the significant fall in industrial investments witnessed during 2015-2016 has bottomed out and demand in Uponor’s core market segments is returning. Uponor’s consolidated net sales reached €265.1 (246.9) million, up 7.4%. A positive currency impact of €3.7 million increased consolidated net sales, mainly originating in the USD and CAD. In constant currency terms, i.e. using Q1/2016 exchange rates, net sales growth was 5.8%. Growth of net sales was robust both in Uponor Infra and in Building Solutions – North America, but also in several key national markets in Building Solutions – Europe, reflecting a clearly improved business environment in both continents. In addition, a small, positive effect is likely to have arisen from customers pre-buying ahead of announced price increases. Building Solutions – Europe reported net sales of €124.3 (123.0) million, up by a modest 1.1%. Net sales grew strongly in several key markets, supported by sales initiatives that bore fruit in pre-fabricated installation unit sales, in particular. A clear exception to the trend was Germany and the UK, both of which saw net sales decline. In the UK, net sales were influenced by the weakening British pound, which made imported products less attractive and, in part, by earlier transformation-related internal measures that caused short term challenges, especially in supply. The unsatisfactory net sales development in Germany was mainly related to overcapacity in the supply of plumbing products that influenced Uponor’s routes to market, in particular, as well as competitive pressures, both in plumbing and in radiant heating systems, from OEM and other low price-performance suppliers. Net sales continued to grow favourably in Building Solutions – North America. The segment’s net sales came to €78.2 (70.7) million, up 10.5%, or 6.7% in USD. In the first quarter of 2016, net sales was very strong as a result of lively sales in Canada and the pre-buying of EP (enhanced polymer) fittings in the U.S. as a result of announced availability constraints. In 2017, irregular order and sales patterns as a result of the EP fittings availability issue in 2016, were still experienced and had a negative impact on net sales growth. Further, sales was curbed by the fact that some business opportunities did not materialise as expected in the first quarter due to external issues, such as weather. Breaking a multi-year negative trend, Uponor Infra reported growth for the first quarter and posted quarterly net sales of €63.1 (54.1) million, up 16.7% year-on-year. Growth was particularly robust in North America, Sweden and Denmark. Uponor’s consolidated gross profit came to €91.4 (87.8) million, a change of €3.6 million. The gross profit margin was 34.5% (35.5%). Comparable gross profit came to €91.6 (88.5) million, or 34.6% (35.8%). The change in gross profit margin was mainly driven by factors related to the EP fittings shortage in the U.S. in 2016, including an increase in freight costs and higher EP resin material cost. Further, partner promotions in the building solutions segments increased from the comparison period in 2016. Operating profit in the first quarter of 2017 came to €14.6 (11.9) million, representing a change of 22.8% year-over-year. Profitability, as measured by the operating profit margin, ticked up to 5.5% (4.8%). Comparable operating profit, i.e. excluding items affecting comparability, came to €15.0 (14.9) million, up 0.8%. Operating profit was burdened by a variety of factors, such as sales mix shifting towards lower margin product groups during the period, increases in overheads and expenses due to initiatives to expand business in the U.S., in particular, as well as continued high level of R&D investment. In line with the transformation programmes reaching towards their end, items affecting comparability amounted to just €-0.4 (€-3.0) million. Building Solutions – Europe’s operating profit came to €6.3 (4.9) million, up 27.9%. The segment’s comparable operating profit amounted to €6.7 (7.5) million, a change of -11.2%. Offsetting the beneficial impact of higher net sales in several markets, the segment’s comparable operating profit declined as a result of lower sales in Germany and marketing costs related to the biennial ISH trade fair in March. The ramp-up of operations in Asia, including the new factory in China, also burdened operating profit to some extent. Building Solutions – North America reported an operating profit of €10.6 (11.1) million, showing a decline of 3.9% from the comparison period but still remaining at a healthy level. The decline in operating profit was partly caused by the repercussions of the shortage in EP resin in 2016, as mentioned above, as well as lower margins due to regional sales mix. Uponor Infra improved its operating profit markedly, by 47.1%, but remained in negative territory at €-1.9 (-3.6) million which, for seasonal reasons, is not unusual for the first quarter. The segment’s comparable operating profit came to €-1.9 (-3.2) million, representing a change of 40.5%. The improvement in profitability was mainly caused by operational leverage due to higher sales volumes, as well as savings from the transformation programme. The largest share of the improvement came from the North American operations, supported by the timely cost saving actions implemented during the fourth quarter of 2016. Uponor Infra’s transformation programme in Europe has, been completed.  Financial expenses at €2.8 (3.4) million were slightly less than in the comparison period. The share of the result in associated companies at -0.5 million is related to the minority share in the joint venture company Phyn, which is still in a development and pilot phase and does not yet generate returns. Profit before taxes for January – March totalled €11.3 (8.6) million. The effect of taxes on profits was €3.9 million, compared to €3.2 million in the first quarter of 2016. The estimated tax rate for the full year is 35%, compared to 31.3% at the year-end of 2016. The profit for the first quarter of 2017 amounted to €7.4 (5.4) million. The rather stable market outlook that prevailed in February 2017, when Uponor announced its 2016 results, has remained materially unchanged. Despite the obvious risks that may materialise, the recent investment behaviour of businesses and consumers indicates that confidence in near-term economic development remains undisturbed. An encouraging improvement in demand has been noted in the European markets, influencing demand for both building solutions and infrastructure solutions, in comparison to sentiment in early 2016. The North American building solutions markets have sustained their healthy levels, despite occasional month-to-month fluctuations in demand. Likewise, demand for infrastructure solutions has picked up in North America. As stated earlier, the recovery thus seems broad-based and is supported by improving confidence, attractive credit terms, immigration and, naturally, pent up demand over the longer term. Plastic resin prices have been on a gradual rising trend in recent months, and Uponor has announced its first price increases to compensate for higher input costs. Further price increases are likely to be announced during the quarter at hand. Assuming that economic development in Uponor's key geographies otherwise continues undisturbed, Uponor repeats its earlier full-year guidance: The Group’s net sales and comparable operating profit are expected to improve from 2016. On 13 February 2017, Uponor estimated that the Group's capital expenditure, excluding any investment in shares, would be in the range of €50-60 million. With the new, planned additions included, the capital expenditure is expected to be close to €60 million in 2017. Funds will be directed towards the development of new products and offering, such as strategically significant hygiene solutions, and the expansion of business in Asia among other activities. Uponor’s financial performance may be affected by a range of strategic, operational, financial, legal, political and hazard risks. A more detailed risk analysis is provided in the section ‘Key risks associated with business’ in the Annual Report 2016. For further information, please contact: Jyri Luomakoski, President and CEO, tel. +358 20 129 2824 Maija Strandberg, CFO, tel. +358 20 129 2830 Uponor is a leading international systems and solutions provider for safe drinking water delivery, energy-efficient radiant heating and cooling and reliable infrastructure. The company serves a variety of building markets including residential, commercial, industrial and civil engineering. Uponor employs about 3,900 employees in 30 countries, mainly in Europe and North America. In 2016, Uponor's net sales totalled €1.1 billion. Uponor is based in Finland and listed on Nasdaq Helsinki. www.uponor.com


News Article | December 14, 2016
Site: www.nature.com

We and others have observed that infection of male adult mice with ZIKV results in infection of the testes3, 4, which is consistent with observed male-to-female5, 6 and male-to-male7 sexual transmission in humans. To address the effects of infection on the male reproductive tract, we performed a longitudinal study in wild-type C57BL/6 mice infected with ZIKV (strains H/PF/2013 (French Polynesia 2013) or mouse-adapted Dakar 41519 (Senegal 1984)) or DENV (serotype 2, strain D2S20). Because ZIKV and DENV do not efficiently antagonize type I interferon (IFN) signalling in mice compared to humans8, animals were treated with a single dose of IFNα and IFNβ receptor 1 (Ifnar1)–blocking monoclonal antibody to facilitate infection and dissemination. When wild-type mice were treated with an isotype-control antibody instead and then infected, ZIKV RNA did not accumulate in the testes (Fig. 1a). In the presence of the anti-Ifnar1 antibody, high levels of viral RNA (105–108 focus-forming unit (FFU) equivalents per g or ml) and infectious virus (up to 108 plaque-forming units (PFU) per g or ml) were detected in the testis, epididymis and the fluid collected from the epididymis within seven days of infection with either of the two ZIKV strains but not DENV (Fig. 1a–c). ZIKV-Dakar replicated to higher levels than ZIKV-H/PF/2013, which is consistent with the enhanced virulence of ZIKV-Dakar in wild-type mice3. Notably, ZIKV RNA and infectious virus were also detected in mature sperm collected from the epididymis (Fig. 1b, c, and Extended Data Fig. 1). At day 7 after inoculation, ZIKV-infected testes appeared similar in size to uninfected testes from age-matched mice and had equivalent weights (Fig. 1d, e). Histological analysis of ZIKV-infected testis and epididymis at day 7 revealed no apparent differences in architecture (Fig. 1f and Extended Data Fig. 2). However, staining for CD45 (a pan-leukocyte marker) was observed in testis sections only from ZIKV-infected animals, with CD45+ cells localizing to the interstitium between the seminiferous tubules (Fig. 1g, column 1). The blood–testis barrier (BTB) remained intact at day 7 after infection, as shown by equivalent staining of the ETV5 transcription factor (which mediates BTB function and testicular immune privilege9) in Sertoli and germ cells in sections from uninfected and ZIKV-infected mice (Fig. 1g, column 2). Furthermore, there was no CD45 staining on the seminiferous tubular side of the BTB, near the TRA98+ germ cells or spermatogonia (Fig. 1g, column 1). A similar pattern of CD45 staining in the testicular interstitium and epididymal epithelium was described in patients infected with HIV10; indeed, we also observed scattered CD45+ cells in the epididymal epithelium of ZIKV-infected mice (Fig. 1g, column 5). However, at day 7, F4/80+ macrophages were not apparent in the testicular interstitium or the lumenal epithelium of the epididymis of ZIKV-infected mice (Fig. 1g, columns 3 and 4). To determine which cells were targeted by ZIKV, we performed in situ hybridization (ISH) for viral RNA at day 7 after infection. In the testis, ZIKV RNA was evident in spermatogonia, primary spermatocytes and the trophic, inhibin B-producing Sertoli cells (Fig. 1h, left), with relative sparing of the androgen-producing Leydig cells. In the cauda epididymis, mature sperm in the lumen stained strongly for ZIKV RNA (Fig. 1h, right) as did sperm cells collected from the epididymis (Extended Data Fig. 1). We followed the consequences of ZIKV infection of the male reproductive tract over time. At day 14 after inoculation, high levels of ZIKV RNA persisted in the testis, epididymis, the fluid from the epididymis and mature sperm of most mice (Fig. 2a). In ZIKV-Dakar-infected animals, there was a noticeable decrease in testis size and weight (Fig. 2b, c). In comparison, no noticeable infection by DENV was observed in the testis at this time point (Extended Data Fig. 3a). Histological analysis of the ZIKV-infected testis at day 14 showed damage to the architecture of the seminiferous tubules with loss of the central ductal lumen (Fig. 2d). This was associated with decreased numbers of TRA98+ germ cells and Lina28a+ type A and B spermatogonia, morphological abnormalities of GATA4+ Sertoli cells and detachment of Sertoli cells from the basement membrane (Fig. 2e and Extended Data Fig. 2). In some regions, large numbers of CD45+ leukocytes were observed, suggesting substantial inflammatory cell infiltration (Fig. 2d left; e, column 1). The absence of ETV5+ cells at this time point indicates loss of integrity of the BTB, which could explain the extent of interstitial inflammation and F4/80+ macrophages in the affected testis. The epididymis of ZIKV-infected animals also showed tissue injury at day 14, as indicated by constriction of the epididymal lumen, thickening of inter-luminal tissue and accumulation of sperm interspersed with necrotic bodies (Fig. 2d, e, right). ISH at day 14 showed progressive evidence of ZIKV RNA in cells of the testis, in the mature lumenal sperm and on cilia layering the inner lumen of the epididymis, similar to day 7 (Fig. 2f). High levels of viral RNA persisted in tissues of the male reproductive tract at 21 days after ZIKV-Dakar inoculation (Fig. 3a), and this was associated with a loss of tissue architecture. Involution of the testis was observed, indicated by their noticeably reduced size and weight (Fig. 3b, c). Histological analysis revealed almost complete destruction of the seminiferous epithelium with constricted tubules after ZIKV infection (Fig. 3d). The populations of spermatogonia, Sertoli cells and 3β-HSD+ Leydig cells were markedly diminished, and this was associated with persistent CD45+ leukocyte infiltration (Fig. 3e and Extended Data Fig. 2). In the epididymis, ZIKV infection resulted in constriction of the lumen with a mass of residual sperm that was interspersed with necrotic bodies (Fig. 3d). ISH showed viral RNA in remaining testicular cells of the damaged testis and in the lumenal sperm of the infected epididymis (Fig. 3f). Damage to the seminiferous tubules in the testis, albeit at lower levels, was also observed in mice infected with the epidemic ZIKV-H/PF/2013 strain at day 28 after infection (Extended Data Fig. 3b, c). The RNA ISH analysis suggested that Sertoli cells were targeted by ZIKV in the testis. Sertoli cells provide a trophic function for spermatogenesis and express high levels of the TAM receptors Tyro3, Axl and Mertk11. Because Axl has recently been postulated as an entry factor for ZIKV infection into cells12, 13, 14, 15, 16, we assessed the effect of a genetic deficiency of Axl on ZIKV infection of the testis and epididymis. As we found high levels of infection in the testis and epididymis in Axl−/− mice (Extended Data Fig. 4a), this TAM receptor probably does not have an essential role in ZIKV pathogenesis in the male reproductive tract. ISH showed strong staining of viral RNA in both Sertoli and germ cells in Axl−/− mice at day 7 after ZIKV infection (Extended Data Fig. 4b). The histological analysis showed that injury of the testis was associated with inflammatory cell infiltration. To assess the role of adaptive immune cells in the pathogenesis of acute disease, we inoculated Rag1−/− mice, which lack both mature B and T cells, with ZIKV after a similar treatment with anti-Ifnar1 antibody. At day 7, we observed high levels of viral RNA in all male reproductive tract tissues (Extended Data Fig. 4a). At day 13, we observed ZIKV RNA in germ and Sertoli cells in Rag1−/− mice, and this was associated with a decrease in TRA98+ germ cells and Lin28a+ spermatogonia and breakdown of the BTB. However, interstitial Leydig cells remained in ZIKV-infected Rag1−/− mice even though the architecture of the seminiferous tubules was altered (Extended Data Fig. 4c–d). Thus, damage to the testis appears to be mediated both by ZIKV infection and adaptive immune responses. To determine the functional consequences of ZIKV-Dakar infection in the testis, we measured the levels of two hormones important for spermatogenesis, testosterone and inhibin B, which are produced by Leydig and Sertoli cells, respectively. At day 7 after ZIKV infection, testosterone levels in homogenates of testes were increased, possibly because of the altered cellular physiology or inflammatory environment associated with viral replication17. By day 14, testosterone levels in ZIKV-infected mice were decreased and remained low at 21 days (Fig. 4a, left). Inhibin B levels were also reduced in ZIKV-infected testes at days 14 and 21 after infection (Fig. 4a, right). We observed diminished total and motile sperm counts from fluid collected from the cauda epididymis at 14 (Fig. 4b) or approximately 42 (Fig. 4c) days after ZIKV inoculation, which was consistent with extensive damage to the seminiferous tubules (Fig. 2d–f and Extended Data Figs 2, 5a, b). We also observed reduced rates of pregnancy and numbers of viable fetuses from females mated with ZIKV-infected males compared to uninfected males (Fig. 4d). Consistent with substantial injury to the testis, there was marked cell death in the seminiferous tubules and lumen of the epididymis at multiple time points, as indicated by TUNEL staining (Fig. 4e) and loss of cellularity (Fig. 3e, f). Thus, in mice, the injury to the male reproductive tract due to ZIKV infection results in decreased sex hormone production and oligospermia. ZIKV pathogenesis in the testis appears distinct from that of mumps virus, which preferentially infects interstitial Leydig cells and causes highly inflammatory acute orchitis18, 19. In most human infections, ZIKV causes a mild febrile illness associated with rash and conjunctivitis. However, severe phenotypes are now appreciated, including Guillain-Barré syndrome20, 21 and congenital abnormalities in fetuses22. ZIKV can be transmitted sexually, in contrast to related flaviviruses, as infectious virus persists in the semen of males23, 24, 25 for up to 80 days after symptom onset2. Our experiments with mouse-adapted ZIKV-Dakar show that infection causes testicular and epididymal damage in mice that can progress to reductions in key sex hormones, destruction of germ and somatic cells in the testis, and loss of mature sperm and fertility. Sertoli cells may be a key target for ZIKV in the testis, resulting in cell dysfunction, detachment from the basement membrane and dissolution of the BTB. Infiltrating inflammatory cells may amplify destruction of the testicular architecture. Although further studies are required, this pathologic process results in decreased male fertility, at least in mice. While Axl is not required for infection of the mouse testis, other TAM or T-cell immunoglobulin and mucin domain (TIM)15 receptors could be important for ZIKV tropism. The establishment of a model of male reproductive tract injury after ZIKV infection will allow the rapid testing of new classes of therapeutic agents26, 27 or vaccines28 to mitigate or prevent disease. Although our data are concerning for yet another unanticipated clinical manifestation of ZIKV infection, we acknowledge these results reflect studies exclusively performed in mice. Nonetheless, genitourinary signs and symptoms, including haematospermia, dysuria and perineal pain5, 6, 29, have been reported in ZIKV-infected humans and ZIKV was recently detected in human spermatozoa30. Longitudinal studies monitoring ZIKV infection in semen and sperm counts seem warranted to define the extent and consequences of this disease process in affected human males.

Loading ISH Inc collaborators
Loading ISH Inc collaborators